MedTrace Logo

Cytokines in Patients With Metastatic Renal Cell Carcinoma of Intermediate Prognosis

NCT00291369 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 456

Last updated 2006-02-16

No results posted yet for this study

Summary

The PERCY Quattro trial has been designed to evaluate the survival benefit of two cytokine treatments, Interleukin-2 (IL2) and/or alpha interferon (IFN), for patients with intermediate chance of response in metastatic renal cell carcinoma.

Eligible patients will be randomly assigned in a two-by-two factorial design to either medroxyprogesterone (MPA), subcutaneous IFN, subcutaneous IL2, or a combination of IFN and IL2.

The primary objective of the study is overall survival; secondary objectives are progression-free survival, response rate, toxicity, and quality of life.

Conditions

  • Metastatic Renal Cell Carcinoma

Interventions

DRUG

Interleukin-2

DRUG

Interferon alfa

DRUG

medroxyprogesterone acetate

Sponsors & Collaborators

  • Centre Leon Berard

    lead OTHER

  • French Immunotherapy Intergroup

    collaborator OTHER

  • SCAPP (Sub-Cutaneous Administration Proleukin Program)

    collaborator UNKNOWN

Principal Investigators

  • Sylvie Negrier, MD, PhD · Centre Leon Berard

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-12-31
Completion
2005-02-28

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00291369 on ClinicalTrials.gov